PITTSBURGH, Pa., Jan. 17, 2006 -- As the leader and founder of High Content Screening (HCS), Cellomics, Inc. is pleased to be the executive sponsor of the Cambridge Healthtech Institute (CHI) annual High Content Analysis (HCA) and RNAi for Pathway Analysis conferences to be held in San Francisco, February 1-3. With continued growth in the use of high content screening (HCS) and analysis for cell biology, CHI is expecting a remarkable turn out at this year’s conference. Cellomics will also hold its annual User Group meeting and a new RNAi tutorial.

The conference brings together scientists from pharmaceutical and biotechnology companies as well as key academic institutions, to address productive uses of high content analysis applications and technology, which heavily influences the research and drug discovery processes. In addition, Cellomics will host a scientific gathering of its customers and other users of HCS technologies from its large installed base to discuss effective implementation of HCS across various therapeutic groups, new technologies, and future trends at the Cellomics User Group meeting on Tuesday, Jan. 31.

“Because we are a business solely focused on high content cellular analysis, the HCA conference is critical to us and our customers., says Dan Calvo, President and CEO of Cellomics. “This is the ideal forum for us to interact with our customers and give them an opportunity to share their experiences of implementing HCA to further their drug discovery efforts. Now that we are part of the Fisher Biosciences Group, we can offer even more complete solutions and expertise to our customers through complementarities with other businesses in the Fisher Biosciences family of companies, including Dharmacon and Pierce. The HCA conference and our annual user group allow us to share this knowledge to help perpetuate the successful use of HCS technology, while simultaneously helping us to better meet the needs of our customers by providing insight on future requirements.”

In addition to the User Group, Cellomics’ is also holding a tutorial for scientists performing RNAi analyses. This tutorial is called “More effective RNAi studies with high content screening” and is designed for scientists using RNAi technologies to learn more about how HCS can complement and add value to their assays. Joseph Zock, Cellomics’ Manager of HCS User Services will conduct this tutorial on Tuesday, Jan. 31, immediately following the Cellomics User Group Meeting. In addition to pre-conference activities, Cellomics’ Lead Application Scientist Scott Keefer will give a presentation entitled “A New Live-Cell Option for High Content Analysis” during the Luncheon Technology Showcase portion of the conference on Wednesday, Feb. 1 and Cellomics’ Senior Product Manager of Informatics Dr. Mark Collins will give a presentation in the Informatics Technology Showcase titled “Don’t Panic! – The Hitchhikers Guide to the HCS Data Challenge” on Thursday, Feb. 2. Cellomics will also have HCS scientists available to discuss technology and biology with all meeting attendees. These scientists will be available in the exhibit hall at Booths 1 and 2. Cellomics will be showcasing its HCS platform, which includes instrumentation, software, and reagents – including the soon to be released Live Cell Imaging Module called the VTI Live and our recently launched BioApplications software for angiogenesis called Tube Formation. Real cell-based assay samples will be available for customers who would like to see how the technology works.

About Cellomics

Cellomics, a business unit within the Fisher Biosciences group, provides complete systems for High Content Screening (HCS) and Analysis (HCA) to drug discovery and systems biology researchers. The Cellomics platform includes automated imaging instrumentation (ArrayScan® and KineticScan® HCS Readers and the cellWoRx^TM High Content Cell Analysis System), BioApplication image analysis software, High Content Informatics (HCi^TM ), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays. Cellomics' proprietary platforms are in use at multiple sites within the top 15 pharmaceutical companies, as well as leading biotechnology companies and academic centers throughout the world. For more information about Cellomics-brand products and services, please visit www.cellomics.com or call 412-770-2200.

About Fisher Biosciences

Fisher Biosciences, a unit of Fisher Scientific International Inc., manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. From fine and high-purity chemicals, clinical diagnostics, proprietary protein-research and cell-culture products, and sterile-liquid-handling systems, to innovative RNA-interference technology and high content screening, Fisher Biosciences serves scientific-research, healthcare, drug-discovery, and general industrial customers around the world.

Click here to download the press release in PDF Format.

Media contact: